In vitro activity of quinupristin/dalfopristin, RP59500, against gram-positive clinical isolates.

Qadri, S M; Ueno, Y; Abu Mostafa, F M; Halim, M

Qadri, S M; Ueno, Y; Abu Mostafa, F M; Halim, M.

Afiliación

Qadri SM; King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Chemotherapy ; 43(2): 94-9, 1997.

Article en En | MEDLINE | ID: mdl-9084917

RESUMEN

Synercid (quinupristin/dalfopristin, RP59500) is a new water-soluble streptogramin which offers some advantages over the commercially available antimicrobials against drug-resistant gram-positive bacteria. Its in vitro activity was compared with ampicillin, augmentin, penicillin, erythromycin, oxacillin and vancomycin against gram-positive bacteria isolated from clinical specimens. Of the 837 gram-positive bacteria tested 834 (99.6%) were inhibited by < 0.6-4.0 mg/l of Synercid. It had excellent activity against both staphylococci and streptococci, including methicillin-resistant staphylococci and vancomycin-resistant enterococci.

Asunto(s)

Farmacorresistencia Microbiana; Bacterias Grampositivas/efectos de los fármacos; Virginiamicina/farmacología; Ampicilina/farmacología; Antibacterianos/farmacología; Combinación de Medicamentos; Enterococcus/efectos de los fármacos; Eritromicina/farmacología; Humanos; Resistencia a la Meticilina; Pruebas de Sensibilidad Microbiana; Oxacilina/farmacología; Staphylococcus aureus/efectos de los fármacos; Streptococcus/efectos de los fármacos; Vancomicina/farmacología

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Farmacorresistencia Microbiana / Virginiamicina / Bacterias Grampositivas Límite: Humans Idioma: En Revista: Chemotherapy Año: 1997 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: Suiza

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links